Disc Medicine reports Q1 2026 results, completes Phase 3 trial enrollment, and expects key data in Q4 2026

Disc Medicine announced its Q1 2026 financial results, highlighting the completion of enrollment for its Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP), with topline data expected in Q4 2026. The company also plans to present updated Phase 2 data for DISC-0974 in myelofibrosis anemia at the ASCO meeting and expects data from ongoing studies of DISC-3405 in polycythemia vera and sickle cell disease by Q4 2026. Disc Medicine ended Q1 with $730 million in cash, supporting operations into 2029. These milestones position the company for multiple important catalysts later this year.